Removal of mtDNA in Plasma by Continous Venovenous Hemofiltration in Sepsis

Not Applicable

• Conditions: Intensive Care Unit
• Interventions: Procedure: continous venovenous hemofiltraion

• Registration Number: NCT04083482
• Lead Sponsor: First People's Hospital of Chenzhou

Brief Summary

The plasma level of mtDNA in sepsis is affected by continous venovenous hemofiltation（CVVH）

Detailed Description

Continous renal replacement therapy （CRRT）has become routine for patients with chronic renal failure ，AKI，fliud overload as well as oliguria in ICU .In clinical patients ，continous venovenous hemofoiltration （CVVH）is actually the method of chioce for CRRT in critically ill and hemodynamic instable patients .CVVH has significant beneficial effects on removing inflammatory cytokines ，improving oxygen index，increasing cardiac index and regulating immune dysfuntion .

Study Timeline

• Study Start: 2018-08-20
• Primary Completion: 2018-09-20
• Status Verified: 2019-09
• Study First Submitted: 2019-09-03
• Study First Submitted QC: 2019-09-05
• Last Update Submitted: 2019-09-05
• Study First Posted: 2019-09-10
• Last Update Posted: 2019-09-10
• Study Completion: 2019-12-31

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

Adult septic patients undergoing CRRT

Exclusion Criteria

1. Missing vists
2. transplatation
3. cancer
4. aquired immunodeficiency syndrome

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Septic patients require CVVH	continous venovenous hemofiltraion	continuous venovenous hemofiltration. Continuous renal replacement therapy（CRRT）has become routine for patients with chronic renal failure ，AKI，fliud overload as well as oliguria in ICU .Continuous venovenous hemofiltration（CVVH）is the method of chioce for CRRT in critical ill .CVVH has significant beneficial effects on removing inflammatory cytokines ，improving oxygen index ，decreasing vasopressor requirements，increasing cardiac index and regulating immune dysfunction .

Primary Outcome Measures

Name	Time	Method
Change of mtDNA concentration in plasma	befor,6hours, 12hours, after CVVH treatment	The specimens in the prefilter and postfilter blood as well as in the ultrafiltrate were obtained at the beginning of CRRT (T0) and 6 h (T6h), 12 h (T12h) after the setup of CVVH.

Trial Locations

Locations (1)

The First Hospital of Chenzhou; 🇨🇳 Chenzhou, Hunan, China